U.S. Biotech Stock News

If you are wondering whether Capital One Financial's current share price offers good value, you are not alone. This article will walk through what the numbers are and what they might mean for you. The stock last closed at US$235.07, with returns of 16.7% over 1 year and 140.7% over 5 years, even though the share price has seen a 0.8% decline over 7 days, 5.1% over 30 days and 5.2% year to date. Recent news around Capital One Financial has focused on its position as a large, diversified...

Vertiv Holdings Co (NYSE:VRT) has launched Vertiv Next Predict, an AI-powered managed service for data center maintenance. The service applies predictive intelligence and advanced analytics across power, cooling, and IT systems to spot anomalies before they disrupt operations. Next Predict is designed to support current and future data center technologies as AI workloads place increasing pressure on critical infrastructure. For investors watching NYSE:VRT, the launch of Vertiv Next Predict...

In recent months, Doximity has drawn renewed attention as analysts and industry commentators highlighted its position in medical information systems and its expanding offerings in hiring, telehealth, and workflow tools for clinicians. An interesting angle is that, despite mixed analyst sentiment and fund commentary, Doximity’s physician-focused network and subscription model are being framed as key advantages within the broader shift toward digital healthcare. With this backdrop, we’ll...

Circle Internet Group (NYSE:CRCL), via Circle Foundation, is supporting the United Nations' Digital Hub of Treasury Solutions (DHoTS). The collaboration brings regulated stablecoins such as USDC into humanitarian aid workflows for faster and more transparent global relief distribution. This initiative introduces blockchain based settlement tools into public sector and nonprofit aid programs. Circle Internet Group, the issuer of USDC, has been a key player in regulated stablecoins focused on...

Wealthfront earnings spark fresh look at the stock Wealthfront (WLTH) just released third quarter and nine month results to October 31, 2025, highlighting higher revenue alongside weaker earnings metrics over the longer period, a mix that gives investors more to unpack. See our latest analysis for Wealthfront. The mixed earnings story appears to line up with the share price pattern this year. The 1 day share price return of 3.14% contrasts with a 30 day share price return of 30.25% and a year...

Ascendis Pharma (ASND) has drawn fresh attention as its shares recently closed at US$228.65. This move has put its recent performance and current valuation back in focus for investors. See our latest analysis for Ascendis Pharma. The recent 1 day share price return of 5.53% adds to a steady pattern, with 30 day and 90 day share price returns of 9.28% and 13.19%. The 1 year total shareholder return of 79.35% and 3 year total shareholder return of 88.14% indicate momentum that investors are...

POET Technologies (NasdaqCM:POET) has received multiple prestigious technology innovation awards for its Teralight optical engine. The company is pursuing a US$150 million direct offering to support acquisitions and expanded R&D. POET Technologies, traded on the NasdaqCM under ticker POET, focuses on optical engines for data centers and AI hardware. Its Teralight product is drawing industry attention at a time when data traffic, AI workloads, and cloud infrastructure demand are all putting...

If you are wondering whether Expand Energy is actually good value at around US$109.49, you are not alone. This article is built to help you answer that question with numbers. The stock has recently moved 10.0% over the last 7 days, while the 30 day return sits at a 1.5% decline and the 1 year return is 6.5% with 38.3% over 3 years. Recent coverage has focused on how investors are reassessing energy names in light of shifting capital allocation priorities and changing sentiment toward growth...

KeyCorp recently reported fourth-quarter and full-year 2025 results, with net interest income rising to US$1,215 million in the quarter and net income reaching US$510 million, while also recording full-year net income of US$1.83 billion and completing a US$200 million share repurchase in the final quarter. Alongside these earnings, the bank unveiled plans to repurchase at least US$1.20 billion of its shares during 2026, underscoring management’s emphasis on capital returns and confidence in...

Ulta Beauty (ULTA) has been drawing attention after recent share price moves, with the stock showing gains over the past month and past three months that stand out within the retail sector. See our latest analysis for Ulta Beauty. That move sits within a stronger trend, with a 12.84% 1 month share price return and 31.68% 3 month share price return helping lift Ulta Beauty to a 1 year total shareholder return of 62.86% as momentum has been building. If Ulta’s recent run has you thinking about...

What the recent analysis means for Ducommun (DCO) Recent analysis of Ducommun (DCO) focuses on its modest backlog growth in aerospace and defense, along with rising costs that have compressed operating margins over the past five years and raised questions about profitability. See our latest analysis for Ducommun. Despite concerns about subdued backlog growth and pressure on margins, Ducommun's share price has climbed strongly. A 30 day share price return of 17.57% and a 1 year total...

Analyst attention shifts to Colgate-Palmolive (CL) Recent calls from Barclays and Wells Fargo have pushed Colgate-Palmolive (CL) back into focus, as both firms reassessed the stock during a period when many investors are rotating toward defensive consumer names. See our latest analysis for Colgate-Palmolive. Those reassessments come as Colgate-Palmolive’s share price has quietly trended higher, with a 30-day share price return of 7.36% and a 90-day share price return of 10.01%. Its 3-year...

If you are wondering whether International Paper at around US$41.84 is priced for a rebound or more weakness, you are not alone. That is exactly what this valuation review will unpack for you. The shares are up 6.0% over the last 30 days, even after a 4.2% slip in the past week, with a 4.0% gain year to date set against a 25.7% decline over the past year and a 28.8% and 9.3% return across the last 3 and 5 years respectively. Recent price moves are being weighed against news flow around the...

What recent performance says about Duke Energy (DUK) Duke Energy (DUK) has seen mixed share performance recently, with a 1-day return of a 1.39% decline and a past 3-month return of a 7.58% decline, while revenue and net income figures remain substantial. See our latest analysis for Duke Energy. At a share price of $117.71, Duke Energy’s recent 30 day share price return of 0.79% contrasts with a 90 day share price decline of 7.58%. The 1 year total shareholder return of 11.55% and 5 year...

If you are wondering whether Hexcel is fairly priced or not at around US$83.18, you are not alone. This article walks through what that number could mean for you as an investor. Over the last week the stock recorded a 1.3% decline, while the 30 day return is 8.8%, the year to date return is 8.2%, the 1 year return is 19.0%, the 3 year return is 26.2% and the 5 year return is 91.8%. These figures may catch the eye if you are weighing up potential upside against risk. Recent news coverage has...

Wells Fargo recently reported fourth-quarter 2025 results that missed Wall Street revenue and net interest income expectations, while simultaneously pushing ahead with cost-cutting, digital investments, and workforce reductions. A key part of this shift is the decision to move its wealth management headquarters to West Palm Beach, Florida, reinforcing a focus on high- and ultra-high-net-worth clients in a growing wealth market. Against this backdrop, we will explore how the wealth management...

BridgeBio Pharma stock reacts to recent performance data BridgeBio Pharma (BBIO) has attracted fresh attention after recent performance figures highlighted its returns and operating profile, prompting investors to reassess how its current share price lines up with fundamentals. See our latest analysis for BridgeBio Pharma. The recent 2.25% 1 day and 47.27% 90 day share price returns, alongside a very large 3 year total shareholder return, point to momentum that investors appear to be linking...

In January 2026, Five9 announced an expanded partnership with Google Cloud to launch a joint Enterprise CX AI solution that integrates Five9’s AI-Infused Intelligent CX Platform with Google Cloud’s Gemini Enterprise for Customer Experience, Gemini models, and Vertex AI to support large enterprises across channels. An interesting aspect of this development is that enterprises can now procure Five9 directly through Google Cloud Marketplace, potentially simplifying deployment, billing, and...

Atlantic Union Bankshares (AUB) has wrapped up FY 2025 with fourth quarter total revenue of US$384.96 million and basic EPS of US$0.77, capping off a trailing twelve month run that delivered US$1.23 billion in revenue and EPS of US$2.03. Over recent quarters, the company has seen quarterly revenue move from US$200.98 million in Q4 2024 to US$195.69 million in Q1 2025, US$297.19 million in Q2, US$354.73 million in Q3, and US$384.96 million in Q4, while basic EPS tracked from US$0.61 to...

Event-driven snapshot of Vaxcyte Vaxcyte (PCVX) has drawn investor attention recently as its clinical-stage vaccine pipeline and current share price of US$53.83 invite closer scrutiny of how the market is pricing this development-focused business. See our latest analysis for Vaxcyte. The recent 7.19% 1 day share price return and 27.47% 90 day share price return suggest momentum has picked up, even though the 1 year total shareholder return of 39.95% decline highlights how volatile sentiment...

FB Financial (FBK) has just closed out FY 2025 with Q4 revenue of US$177.4 million and basic EPS of US$1.08, setting a clear earnings marker for investors to work from. Over the past year, the company has seen quarterly revenue move from US$123.3 million in Q4 2024 to US$177.4 million in Q4 2025, while basic EPS over the same quarters went from US$0.81 to US$1.08. Trailing twelve month EPS sits at US$2.47 on revenue of US$516.7 million. With a current net profit margin of 23.7% compared with...

Blackstone stock performance snapshot Blackstone (BX) is back on many investors’ screens after a mixed run in recent months, with the share price near US$154.91 and returns varying between the past month and past 3 months. The stock shows a 1 day return of about a 1% decline, a 7 day return of about a 4% decline, and a month performance close to flat. Over the past 3 months it shows a small gain, alongside a weaker year to date and 1 year picture. See our latest analysis for...

Caesars Entertainment (NasdaqGS:CZR) announced plans to open a new Caesars Sportsbook at Rampart Casino, subject to regulatory approval. The company also reported the resignation of Board director Don R. Kornstein, marking a change in its governance lineup. Caesars Entertainment, a major operator of casinos and sports betting offerings in the United States, is expanding its branded sportsbook footprint with the planned Rampart Casino location. For investors, this ties directly to the...

If you are wondering whether Corcept Therapeutics at around US$41.30 is priced attractively or not, the key question is how that share price lines up with the company’s underlying value. The stock has seen sharp moves recently, with a 16.7% gain over the past 7 days, a 49.6% decline over the last 30 days, an 8.1% return year to date, a 33.7% decline over the past year, an 80.0% return over 3 years, and a 43.9% return over 5 years. These swings have kept Corcept Therapeutics on many...